Future Pharmacology最新文献_第7页

Role of Senescence-Resumed Proliferation in Keloid Pathogenesis 衰老恢复增生在瘢痕疙瘩发病中的作用

Future Pharmacology Pub Date : 2023-02-07 DOI: 10.3390/futurepharmacol3010014

Ching-Yun Wang, Chieh-Wen Wu, Ting-Yi Lin

引用次数: 1

A Synergistic Antibacterial Platform Combining Low−Temperature Photothermal Therapy and Antibiotic Therapy 低温光热治疗与抗生素治疗的协同抗菌平台

Future Pharmacology Pub Date : 2023-02-07 DOI: 10.3390/futurepharmacol3010013

Qiming Zhang, Lei Chang, Caixia Sun, Wanchao Zuo, Shibo Zhang, Cong Liu, Shuyue Deng, Pengcheng Wu, Panpan Dai, Jianjun Dai, Yanmin Ju

{"title":"A Synergistic Antibacterial Platform Combining Low−Temperature Photothermal Therapy and Antibiotic Therapy","authors":"Qiming Zhang, Lei Chang, Caixia Sun, Wanchao Zuo, Shibo Zhang, Cong Liu, Shuyue Deng, Pengcheng Wu, Panpan Dai, Jianjun Dai, Yanmin Ju","doi":"10.3390/futurepharmacol3010013","DOIUrl":"https://doi.org/10.3390/futurepharmacol3010013","url":null,"abstract":"Antimicrobial resistance has brought great burden to global public health. Alternative strategies are needed to reduce the development of drug resistance. Herein, we have developed an effective synergistic antibacterial strategy combining low−temperature photothermal therapy (LT−PTT) with antibiotic therapy, improving the bactericidal efficiency to avoid antimicrobial resistance. Copper sulfide templated with bovine serum albumin (CuS−BSA) nanoparticles were selected as the photothermal agent, and co−loaded into the hydrogel (Gel) with mupirocin. The Gel could slow down the release rate of CuS−BSA and mupirocin, thereby prolonging the effective drug reaction time. More importantly, when applying near−infrared laser irradiation, the antibacterial activity of the platform could be enhanced greatly by LT−PTT effect of CuS−BSA nanoparticles. In vitro and in vivo results both confirmed that the antibacterial efficacy of the synergistic therapeutic strategy was improved greatly with complete bacterial removal. Overall, this platform has posed a potential strategy to reduce the development of drug resistance and improve patient compliance.","PeriodicalId":12592,"journal":{"name":"Future Pharmacology","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74052395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aspirin Therapy, Cognitive Impairment, and Dementia—A Review 阿司匹林治疗、认知障碍和痴呆——综述

Future Pharmacology Pub Date : 2023-02-01 DOI: 10.3390/futurepharmacol3010011

E. H. Thong, E. Lee, Choi-Ying Yun, Tony Y. W. Li, C. Sia

{"title":"Aspirin Therapy, Cognitive Impairment, and Dementia—A Review","authors":"E. H. Thong, E. Lee, Choi-Ying Yun, Tony Y. W. Li, C. Sia","doi":"10.3390/futurepharmacol3010011","DOIUrl":"https://doi.org/10.3390/futurepharmacol3010011","url":null,"abstract":"Background: Dementia is associated with a greater burden of cardiovascular risk factors. There is a significant vascular contribution to dementia, and aspirin may play a role in targeting this vascular dysregulation via its anti-inflammatory and antiplatelet effects. We provide an overview of the effects of aspirin therapy on the prevention of dementia and cognitive decline in patients with or without dementia and/or cognitive impairment. Methods: We performed a search for studies enrolling adults with or without dementia or MCI and comparing aspirin with placebo, usual care, or active control with respect to cognitive outcomes. Results: We describe aspirin’s effects on the primary prevention of cognitive impairment and various subtypes of dementia, as well as its role in cognitive decline in certain subsets of patients, including those with cerebral small vessel disease (CVSD), coronary heart disease (CHD), and gender differences. Overall, the benefits of aspirin in preventing dementia and cognitive decline remain inconclusive. The majority of cohort studies investigating aspirin’s role in preventing cognitive decline or dementia looked promising, but this was not supported in most randomised controlled trials. However, aspirin may still be beneficial in certain subgroups of patients (such as CHD, VD, and CSVD) and warrants further investigation.","PeriodicalId":12592,"journal":{"name":"Future Pharmacology","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90437207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Acute Promyelocytic Leukemia (APL): A Review of the Classic and Emerging Target Therapies towards Molecular Heterogeneity 急性早幼粒细胞白血病(APL):经典和新兴靶向治疗分子异质性的综述

Future Pharmacology Pub Date : 2023-02-01 DOI: 10.3390/futurepharmacol3010012

Tâmara Dauare de Almeida, F. Evangelista, A. Sabino

引用次数: 2

Acknowledgment to the Reviewers of Future Pharmacology in 2022 对2022年未来药理学审稿人的感谢

Future Pharmacology Pub Date : 2023-01-17 DOI: 10.3390/futurepharmacol3010010

引用次数: 0

Anxiolytic/Sedative Effect of Monoterpene (–)-Borneol in Mice and In Silico Molecular Interaction with GABAA Receptor 单萜(-)-冰片对小鼠的抗焦虑/镇静作用及其与GABAA受体的硅分子相互作用

Future Pharmacology Pub Date : 2023-01-13 DOI: 10.3390/futurepharmacol3010009

Maurício P. M. Amaral, Marcelo Pereira da Silva Junior, Francisco das Chagas Alves Lima, S. Gutierrez, D. Arcanjo, R. C. M. Oliveira

{"title":"Anxiolytic/Sedative Effect of Monoterpene (–)-Borneol in Mice and In Silico Molecular Interaction with GABAA Receptor","authors":"Maurício P. M. Amaral, Marcelo Pereira da Silva Junior, Francisco das Chagas Alves Lima, S. Gutierrez, D. Arcanjo, R. C. M. Oliveira","doi":"10.3390/futurepharmacol3010009","DOIUrl":"https://doi.org/10.3390/futurepharmacol3010009","url":null,"abstract":"Anxiety is a normal behavioral component. When it is too frequent or appears in inappropriate contexts, it can be considered pathological. Benzodiazepines (BDZs) are drugs with clinical success in anxiety treatment. BDZs act as allosteric modulators of the γ- aminobutyric acid A receptor (GABAAR). However, these drugs cause adverse effects. Despite the therapeutic advances obtained with BDZs, the search for anxiolytics with fewer adverse effects is ongoing. Studies with monoterpene (–)-borneol [(–)-BOR] demonstrated pharmacological properties such as a partial agonist effect of GABAAR and an anticonvulsive effect. On the other hand, no work has been developed evaluating the anxiolytic/sedative potential. The objective of this study was to investigate the anxiolytic/sedative effects of (–)-BOR in animal models at doses of 25, 50, and 100 mg/kg (i.p.) and whether there was a molecular interaction with GABAAR. The anxiolytic effect of monoterpene (–)-BOR was tested on Swiss mice (25–30 g) in three anxiety models: the elevated plus maze test, the open field test, and the light-dark box test. The thiopental-induced sleep time model was a drug screen for the sedative and hypnotic activity related to GABAARs. In the molecular docking, the interaction between the GABAAR molecule and (–)-BOR was performed using the AutoDock 4.2.6 program. The results demonstrated that (–)-BOR has sedative and anxiolytic activity. The molecular docking study revealed that (–)-BOR can interact with GABAARs through hydrogen bonds.","PeriodicalId":12592,"journal":{"name":"Future Pharmacology","volume":"71 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73660032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Calcitonin Gene-Related Peptide (CGRP)-Targeted Treatments—New Therapeutic Technologies for Migraine 降钙素基因相关肽(CGRP)靶向治疗——偏头痛的新治疗技术

Future Pharmacology Pub Date : 2023-01-12 DOI: 10.3390/futurepharmacol3010008

L. Sangalli, S. Brazzoli

{"title":"Calcitonin Gene-Related Peptide (CGRP)-Targeted Treatments—New Therapeutic Technologies for Migraine","authors":"L. Sangalli, S. Brazzoli","doi":"10.3390/futurepharmacol3010008","DOIUrl":"https://doi.org/10.3390/futurepharmacol3010008","url":null,"abstract":"Migraine is ranked as the third most common disorder worldwide and is considered one of the most disabling neurological conditions. Its treatment has mostly relied on medications that were non-specifically developed for migraine, thus accompanied by low adherence, inadequate effectiveness and intolerable side effects. These recent years have seen the development of new migraine-specific therapies targeting the calcitonin gene-related peptide (CGRP) and its receptor. These newly developed therapies, the small molecule gepants targeting the CGRP receptor and the anti-CGRP monoclonal antibodies (mAbs), are currently available in the market and FDA-approved for migraine treatment. As they are migraine-specific therapies, they largely expand their use to patients that could not tolerate previous treatments, either for systemic contraindications or drug-to-drug interactions, or where any other available option was not efficacious. Randomized controlled trials have demonstrated the efficacy of these new medications, with minor adverse effects reported (most commonly nausea and constipation). This article will review the mechanism of action, indications, contraindications, and tolerability profile of gepants and anti-CGRP mAbs, by summarizing the available literature. Finally, avenues for future research will be identified, so that upcoming controlled studies may be designed to fill such gaps.","PeriodicalId":12592,"journal":{"name":"Future Pharmacology","volume":"220 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76070378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Perspectives for Targeting Ezrin in Cancer Development and Progression 靶向Ezrin在癌症发生和进展中的研究进展

Future Pharmacology Pub Date : 2023-01-09 DOI: 10.3390/futurepharmacol3010005

Jean Carlos Lipreri da Silva, H. P. Vicari, J. Machado-Neto

引用次数: 2

SARS-CoV-2 Mpro Inhibitors: Achieved Diversity, Developing Resistance and Future Strategies SARS-CoV-2 Mpro抑制剂:实现多样性，发展耐药性和未来策略

Future Pharmacology Pub Date : 2023-01-09 DOI: 10.3390/futurepharmacol3010006

Conrad Fischer, Jenson R. Feys

{"title":"SARS-CoV-2 Mpro Inhibitors: Achieved Diversity, Developing Resistance and Future Strategies","authors":"Conrad Fischer, Jenson R. Feys","doi":"10.3390/futurepharmacol3010006","DOIUrl":"https://doi.org/10.3390/futurepharmacol3010006","url":null,"abstract":"While the COVID-19 pandemic seems to be on its decline, the unclear impacts of long-COVID cases, breakthrough infections in immunocompromised individuals, vaccine hesitancy, and inhomogeneous health-care accessibility constitute a not to be underestimated threat. These cases, along with pandemic preparedness, ask for an alert identification of new drugs and the optimization of existing drugs as therapeutic treatment options for this and potential future diseases. Mpro inhibitors were identified early on as potent drug candidates against coronaviruses, since they target viable processing machinery within the virus, i.e., the main protease that cleaves the polyproteins encoded by the viral RNA into functional proteins. Different strategies, including reversible and irreversible inhibition as well as allosteric inhibitors, mostly from drug repurposing endeavors, have been explored in the design of potent SARS-CoV-2 Mpro antivirals. Ambitious screening efforts have uttered an outstanding chemical and structural diversity, which has led to half a dozen lead compounds being currently in clinical trials and the emergency FDA approval of ritonavir-boosted nirmatrelvir as a COVID-19 therapeutic. This comprehensive analysis of the achieved inhibitor diversity sorted into irreversible, reversible, and allosteric Mpro binders, along with a discussion of emerging resistance reports and possible evasion strategies, is aimed at stimulating continuing Mpro drug design efforts.","PeriodicalId":12592,"journal":{"name":"Future Pharmacology","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87082235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Flustramine Q, a Novel Marine Origin Acetylcholinesterase Inhibitor from Flustra foliacea 氟曲明Q:一种新型海产乙酰胆碱酯酶抑制剂

Future Pharmacology Pub Date : 2023-01-06 DOI: 10.3390/futurepharmacol3010003

N. M. Kowal, X. Di, S. Omarsdottir, E. Olafsdottir

{"title":"Flustramine Q, a Novel Marine Origin Acetylcholinesterase Inhibitor from Flustra foliacea","authors":"N. M. Kowal, X. Di, S. Omarsdottir, E. Olafsdottir","doi":"10.3390/futurepharmacol3010003","DOIUrl":"https://doi.org/10.3390/futurepharmacol3010003","url":null,"abstract":"The bryozoan Flustra foliacea produces a range of indole alkaloids, and some have shown weak antibiotic, muscle-relaxant and cytotoxic properties; however, most of them have not been tested for bioactivity. Many of these alkaloids possess a physostigmine scaffold, and physostigmine is a well-known acetylcholinesterase (AChE) inhibitor. AChE inhibitors are of interest as drug leads in neurodegenerative diseases and are currently used in symptomatic treatment of Alzheimer’s disease (AD). In this study, the AChE inhibitory activity of Flustra alkaloids was studied in vitro using the colorimetric method of Ellman and AChE from Electrophorus electricus. Twenty-five compounds isolated from the Icelandic bryozoan F. foliacea were screened at a 100 µM concentration. Two of them, flustramine E and flustramine I, showed inhibition of 48%, and flustramine Q showed 82% inhibition. For flustramine Q, the IC50 was 9.6 µM. Molecular modelling and docking studies indicated that simple in silico designed derivatives of flustramine Q could have potential for increased potency. Marine natural products including brominated indole alkaloids from Flustra foliacea are an interesting new source of AChE inhibitors with potential towards central nervous system disorders, e.g., Alzheimer’s disease.","PeriodicalId":12592,"journal":{"name":"Future Pharmacology","volume":"236 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85318556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0